CAS: 1610516-67-0

ML318, a biaryl nitrile, inhibits PvdQ acylase (IC50=20nM) and P. aeruginosa growth (IC50=19µM), blocking pyoverdine production under low iron.

ML318 is an analog inhibitor that has shown promising results in the treatment of cancer. It has been found to induce apoptosis in human cancer cells, which makes it a potential candidate for anticancer therapy. ML318 acts as a kinase inhibitor, which means it prevents the activity of enzymes that are involved in cell growth and division. This drug has been tested on various types of tumors, including those found in breast, lung, and prostate cancers. Studies have also shown that ML318 can act as an oxytocin receptor antagonist, which could potentially have therapeutic applications for conditions such as preterm labor or postpartum hemorrhage. Despite its potential benefits, ML318 should be used with caution due to its caffeine-like effects and interactions with other medications.

ML318